Northwest & Ethical Investments’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-35,242
| Closed | -$1.9M | – | 537 |
|
|
2025
Q4 | $1.9M | Sell |
35,242
-70,569
| -67% | -$3.39M | 0.04% | 257 |
|
|
2025
Q3 | $4.77M | Hold |
105,811
| – | – | 0.11% | 190 |
|
|
2025
Q2 | $4.9M | Sell |
105,811
-56,276
| -35% | -$2.76M | 0.12% | 184 |
|
|
2025
Q1 | $9.88M | Buy |
162,087
+88,588
| +121% | +$5.16M | 0.27% | 115 |
|
|
2024
Q4 | $4.16M | Buy |
73,499
+57,331
| +355% | +$3.2M | 0.11% | 197 |
|
|
2024
Q3 | $837K | Buy |
16,168
+2,820
| +21% | +$132K | 0.02% | 315 |
|
|
2024
Q2 | $554K | Sell |
13,348
-78,345
| -85% | -$3.51M | 0.02% | 333 |
|
|
2024
Q1 | $4.97M | Sell |
91,693
-73,416
| -44% | -$3.74M | 0.14% | 174 |
|
|
2023
Q4 | $8.47M | Sell |
165,109
-75,784
| -31% | -$3.98M | 0.26% | 127 |
|
|
2023
Q3 | $14M | Buy |
240,893
+8,451
| +4% | +$518K | 0.47% | 71 |
|
|
2023
Q2 | $14.9M | Buy |
232,442
+27,670
| +14% | +$1.86M | 0.48% | 66 |
|
|
2023
Q1 | $14.2M | Buy |
204,772
+50,014
| +32% | +$3.53M | 0.47% | 69 |
|
|
2022
Q4 | $11.1M | Buy |
154,758
+81,271
| +111% | +$6.13M | 0.38% | 88 |
|
|
2022
Q3 | $5.22M | Buy |
73,487
+7,525
| +11% | +$546K | 0.21% | 147 |
|
|
2022
Q2 | $5.08M | Sell |
65,962
-86,603
| -57% | -$6.6M | 0.19% | 151 |
|
|
2022
Q1 | $11.1M | Buy |
152,565
+131,215
| +615% | +$8.81M | 0.36% | 88 |
|
|
2021
Q4 | $1.33M | Sell |
21,350
-24,405
| -53% | -$1.43M | 0.04% | 274 |
|
|
2021
Q3 | $2.71M | Sell |
45,755
-49,986
| -52% | -$3.29M | 0.09% | 215 |
|
|
2021
Q2 | $6.4M | Sell |
95,741
-151,181
| -61% | -$9.86M | 0.21% | 134 |
|
|
2021
Q1 | $15.6M | Buy |
246,922
+54,096
| +28% | +$3.37M | 0.55% | 58 |
|
|
2020
Q4 | $12M | Buy |
192,826
+42,722
| +28% | +$2.63M | 0.46% | 72 |
|
|
2020
Q3 | $9.05M | Sell |
150,104
-33,828
| -18% | -$2.04M | 0.4% | 84 |
|
|
2020
Q2 | $10.8M | Buy |
183,932
+15,146
| +9% | +$906K | 0.51% | 60 |
|
|
2020
Q1 | $9.41M | Sell |
168,786
-5,755
| -3% | -$352K | 0.55% | 46 |
|
|
2019
Q4 | $11.2M | Sell |
174,541
-2,649
| -1% | -$152K | 0.5% | 51 |
|
|
2019
Q3 | $8.99M | Buy |
177,190
+11,731
| +7% | +$551K | 0.44% | 69 |
|
|
2019
Q2 | $7.5M | Sell |
165,459
-11,810
| -7% | -$550K | 0.38% | 84 |
|
|
2019
Q1 | $8.46M | Buy |
177,269
+76,856
| +77% | +$3.83M | 0.44% | 58 |
|
|
2018
Q4 | $5.22M | Buy |
100,413
+41,323
| +70% | +$2.22M | 0.31% | 101 |
|
|
2018
Q3 | $3.67M | Buy |
59,090
+10,730
| +22% | +$637K | 0.23% | 133 |
|
|
2018
Q2 | $2.68M | Sell |
48,360
-560
| -1% | -$30.2K | 0.18% | 172 |
|
|
2018
Q1 | $3.09M | Buy |
48,920
+13,520
| +38% | +$870K | 0.21% | 157 |
|
|
2017
Q4 | $2.17M | Buy |
35,400
+15,900
| +82% | +$995K | 0.14% | 208 |
|
|
2017
Q3 | $1.24M | Sell |
19,500
-6,600
| -25% | -$385K | 0.08% | 264 |
|
|
2017
Q2 | $1.45M | Buy |
26,100
+10,000
| +62% | +$544K | 0.1% | 241 |
|
|
2017
Q1 | $876K | Buy |
+16,100
| New | +$883K | 0.06% | 298 |
|
Other funds holding BMY
Northwest & Ethical Investments's BMY Position: Q1 2026 in Review
Northwest & Ethical Investments sold out of Bristol-Myers Squibb (BMY) in Q1 2026, closing a stake of 35,242 shares — an estimated $1.9M sold.
Northwest & Ethical Investments first reported a position in BMY in Q1 2017 and held it in 36 quarters. The position peaked at $15.6M in Q1 2021. 2,532 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Northwest & Ethical Investments reported no remaining Bristol-Myers Squibb position as of Q1 2026 after selling out during the quarter.
- Northwest & Ethical Investments sold 35,242 Bristol-Myers Squibb shares in Q1 2026, an estimated $1.9M.
- Northwest & Ethical Investments first reported a position in Bristol-Myers Squibb in Q1 2017 and held it in 36 quarters.
- Northwest & Ethical Investments's Bristol-Myers Squibb position peaked at $15.6M in Q1 2021.
- 2,532 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Northwest & Ethical Investments's 13F filing for Q1 2026, filed 14 May 2026.